Stock Track | Abivax Soars 5.54% as Analyst Initiates Coverage with Bullish Outlook-To The Moon - Tiger Brokers Online Investing Community

Like
Comment
Favorite

Stock Track | Abivax Soars 5.54% as Analyst Initiates Coverage with Bullish Outlook

Stock Track2024-12-04

Shares of Abivax S.A. (ABVX) rallied 5.54% in Wednesday's intraday trading session, following a positive initiation note from an analyst. The biopharmaceutical company's stock surged after JMP Securities initiated coverage with an Outperform rating and a price target of $33, reflecting significant upside potential from current levels.

According to the analyst, Abivax's pipeline, including its lead candidate for ulcerative colitis and other inflammatory bowel diseases, presents a promising opportunity. The firm cited the drug's potential to address a large unmet medical need and market, contributing to the bullish outlook.

The favorable coverage from JMP Securities highlights growing optimism around Abivax's prospects, driving the stock's surge. Investors appeared to respond positively to the analyst's confidence in the company's future, bidding up shares in the biopharmaceutical firm.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1165684470?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-12-05 00:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165684470","market":"us","top_or_hot":-1,"title":"Stock Track | Abivax Soars 5.54% as Analyst Initiates Coverage with Bullish Outlook","media":"Stock Track","content":"<p>Shares of Abivax S.A. (ABVX) rallied 5.54% in Wednesday's intraday trading session, following a positive initiation note from an analyst. The biopharmaceutical company's stock surged after JMP Securities initiated coverage with an Outperform rating and a price target of $33, reflecting significant upside potential from current levels.</p>\n\n<p>According to the analyst, Abivax's pipeline, including its lead candidate for ulcerative colitis and other inflammatory bowel diseases, presents a promising opportunity. The firm cited the drug's potential to address a large unmet medical need and market, contributing to the bullish outlook.</p>\n\n<p>The favorable coverage from JMP Securities highlights growing optimism around Abivax's prospects, driving the stock's surge. Investors appeared to respond positively to the analyst's confidence in the company's future, bidding up shares in the biopharmaceutical firm.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Abivax Soars 5.54% as Analyst Initiates Coverage with Bullish Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Abivax Soars 5.54% as Analyst Initiates Coverage with Bullish Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-12-05 00:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Abivax S.A. (ABVX) rallied 5.54% in Wednesday's intraday trading session, following a positive initiation note from an analyst. The biopharmaceutical company's stock surged after JMP Securities initiated coverage with an Outperform rating and a price target of $33, reflecting significant upside potential from current levels.</p>\n\n<p>According to the analyst, Abivax's pipeline, including its lead candidate for ulcerative colitis and other inflammatory bowel diseases, presents a promising opportunity. The firm cited the drug's potential to address a large unmet medical need and market, contributing to the bullish outlook.</p>\n\n<p>The favorable coverage from JMP Securities highlights growing optimism around Abivax's prospects, driving the stock's surge. Investors appeared to respond positively to the analyst's confidence in the company's future, bidding up shares in the biopharmaceutical firm.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABVX","symbol_name":"Abivax S.A.","start_time":0,"source_url":"","article_id":"1165684470","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165684470","pubTimestamp":1733329098,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Abivax S.A.  rallied 5.54% in Wednesday's intraday trading session, following a positive initiation note from an analyst. The biopharmaceutical company's stock surged after JMP Securities initiated coverage with an Outperform rating and a price target of $33, reflecting significant upside potential from current levels.According to the analyst, Abivax's pipeline, including its lead candidate for ulcerative colitis and other inflammatory bowel diseases, presents a promising opportunity. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABVX":"Abivax S.A."},"translate_title":"分析师首次报道看涨前景，Abivax股价飙升5.54%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABVX":1},"content_text":"Shares of Abivax S.A. (ABVX) rallied 5.54% in Wednesday's intraday trading session, following a positive initiation note from an analyst. The biopharmaceutical company's stock surged after JMP Securities initiated coverage with an Outperform rating and a price target of $33, reflecting significant upside potential from current levels.\nAccording to the analyst, Abivax's pipeline, including its lead candidate for ulcerative colitis and other inflammatory bowel diseases, presents a promising opportunity. The firm cited the drug's potential to address a large unmet medical need and market, contributing to the bullish outlook.\nThe favorable coverage from JMP Securities highlights growing optimism around Abivax's prospects, driving the stock's surge. Investors appeared to respond positively to the analyst's confidence in the company's future, bidding up shares in the biopharmaceutical firm.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}